GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Current Accrued Expense

BeiGene (STU:49B) Current Accrued Expense : €394 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Current Accrued Expense?

BeiGene's Current Accrued Expense for the quarter that ended in Sep. 2024 was €394 Mil.

BeiGene's quarterly Current Accrued Expense increased from Mar. 2024 (€331 Mil) to Jun. 2024 (€351 Mil) and increased from Jun. 2024 (€351 Mil) to Sep. 2024 (€394 Mil).

BeiGene's annual Current Accrued Expense declined from Dec. 2021 (€305 Mil) to Dec. 2022 (€220 Mil) but then increased from Dec. 2022 (€220 Mil) to Dec. 2023 (€358 Mil).


BeiGene Current Accrued Expense Historical Data

The historical data trend for BeiGene's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Current Accrued Expense Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.47 181.92 305.43 219.75 358.07

BeiGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 248.92 358.07 331.23 350.53 394.16

BeiGene Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


BeiGene Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of BeiGene's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

BeiGene Headlines

No Headlines